Results 131 to 140 of about 3,281,012 (248)

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Carbon solubility and liquid-liquid immiscibility in Fe-C-S ternary system up to 6 GPa: implications for the core of small planetary bodies. [PDF]

Prog Earth Planet Sci
Zhao B, Morard G, Manthilake G, Parisiades P, Yang J, Fei Y, Le Godec Y, Kondo N, Yoshino T, Antonangeli D.   +9 more
europepmc   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Clinical Nurse Specialists' Perceptions of Competency and Self-Efficacy in Evidence-Based Practice and Implementation Science. [PDF]

Worldviews Evid Based Nurs
Shay A, McNett M, Tucker S, Fulton JS.
europepmc   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

Starting Medical Research: A Practical Guide

, 2008
An ideal concise pocket guide for anyone beginning medical research projects – packed full of practical, useful advice. The author’s have turned their extensive experience in the fields of medical research and education into a handy, comprehensive, no ...
Curran, Julie, Curran, Stephen
core   +1 more source

Transduction efficiency in clinical CAR T cell products: A retrospective study at a single center. [PDF]

Mol Ther Adv
Shao L, Prochazkova M, Cai Y, Lee Han K, Martin K, Shi R, Yang R, Ma J, Zheng Y, Garces P, Frodigh SE, Pham V, Zhang N, Somerville RP, Stroncek DF, Jin P.   +15 more
europepmc   +1 more source

Partial FAK suppression promotes tumor growth, an effect reversed by macrophage p110δ PI3K inactivation

Molecular Oncology, EarlyView.
Partial inhibition of focal adhesion kinase (FAK) can paradoxically promote tumor growth, rather than simply producing a weaker antitumor effect than that observed with strong FAK suppression. In breast cancer and melanoma models, targeting p110δ PI3K, particularly in macrophages, counteracted these tumor‐promoting effects, highlighting the importance ...
Lydia Xenou, Niki Tzenaki, Anna Tsapara, Maria Tzardi, Evangelia A. Papakonstanti   +4 more
wiley   +1 more source

Real-World Outcomes of Lenvatinib in Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Multicentre Retrospective Study. [PDF]

Cancers (Basel)
Chan WL, Tin WW, Wong KC, Kwok CC, Chow JCH, Liu TC, Cheung GT, Choi WY, Au LJ, To JC, Lo GY, Hou LY, Yeung KK, Leung HL, Kwong DL.   +14 more
europepmc   +1 more source